Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Customer risk | Total net revenue

Schedule of concentration risk

Through September 30, 2018, substantially all of the Company's product revenue has been derived from the sale of Mytesi. The Company earned Mytesi revenue primarily from three major pharmaceutical distributors in the United States, each of which amounted to a percentage of total net revenue of at least 10%. Revenue earned from each as a percentage of total net revenue follow:  [OPEN will get updated percentages from Veronica]
Consolidated (percentage of total net sales)	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2018		2017		2018		2017
Customer 1	34	%	11	%	28	%	4	%
Customer 2	28	%	9	%	28	%	3	%
Customer 3	25	%	12	%	25	%	5	%
	88	%	32	%	81	%	13	%

Credit risk | Total accounts receivable

Schedule of concentration risk

	As of		As of
	September 30,		December 31,
	2018		2017
Customer 1	35	%	30	%
Customer 2	29	%	31	%
Customer 3	26	%	35	%